Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:AIMD

Ainos Q1 2025 Earnings Report

Ainos logo
$1.65 -0.05 (-2.94%)
As of 02:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ainos EPS Results

Actual EPS
-$1.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q1 2025
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q1 2025 Press ReleasePress Release
(8-K)
Ainos' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Ainos Earnings Headlines

Interview with Jack Lu, Head of Corporate Development of Ainos, Inc.
June 29, 2026  |  msn.comhttps://www.msn.com/en-us/news/technology/interview-with-jack-lu-head-of-corporate-development-of-ainos-inc/ar-AA26NOQj
Ainos, Inc.: Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program
June 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68791912-ainos-inc-ainos-expands-smell-ai-platform-into-digital-breath-intelligence-through-national-taiwan-university-research-program-200.htm
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
July 17 at 1:00 AM  |  InvestorPlace (Ad)
Ainos Sinks on Release of New Article
June 3, 2026  |  baystreet.cahttps://www.baystreet.ca/techinsider/5585/Ainos-Sinks-on-Release-of-New-Article
Ainos Expands Smell AI into Healthcare Infrastructure Through New NTUH Study
June 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/technology/ainos-expands-smell-ai-into-healthcare-infrastructure-through-new-ntuh-study/ar-AA24yNTf
Ainos Insider Trading Activity | NASDAQ:AIMD | Benzinga
May 30, 2026  |  benzinga.comhttps://www.benzinga.com/quote/AIMD/insider-trades
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD) (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

View Ainos Profile
Earnings Tools